Esperion Therapeutics Inc

Most Recent

  • uploads///Spark ana reco
    Company & Industry Overviews

    What Spark Therapeutics’ Valuation Trend Indicates

    Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.

    By Kenneth Smith
  • uploads///Axovant ana reco
    Company & Industry Overviews

    Analyzing Axovant Sciences’ Valuation Metrics

    In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given it a “buy” rating, and five have given it a “hold.”

    By Kenneth Smith
  • uploads///ESPR
    Company & Industry Overviews

    Analyzing the Research Pipeline of Esperion Therapeutics

    Esperion Therapeutics’ development program for bempedoic acid consists of four clinical studies.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.